National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine
A cancer vaccine consisting of autologous dendritic cells transfected with autologous tumor mRNA and the human CD40 ligand (CD40L) gene with immunostimulatory and antitumor activities. Vaccination with autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine may elicit a cytotoxic T cell response against tumor cells from which the autologous tumor mRNA was derived. When expressed by dendritic cells, tumor antigens and the co-stimulatory molecule CD40L, which binds to CD40 receptors on antigen presenting cells (APC), facilitate both humoral and cellular immune responses against tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:Autologous Dendritic Cell and Tumor mRNA Human CD40L Vaccine



Previous:autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, autologous anti-PSMA gene-modified T-cells, autologous dendritic cell-adenovirus CCL21 vaccine, autologous dendritic cell-adenovirus p53 vaccine, autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
Next:autologous dendritic cell-tumor fusion vaccine, autologous dinitrophenyl-modified ovarian cancer vaccine, autologous EBV-CTL CD19CAR zeta, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov